FranΓ§aisπ See the interactive version (live chart) β
For Cardinal Health, we replayed every analyst price target of the past 12 months and measured the real outcome: 71% were profitable, average return +28% (114 calls). At 3 months: +6% average return (56% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Morgan Stanley | 20 | 75% | +34% |
| UBS | 15 | 80% | +31% |
| Barclays | 14 | 50% | +21% |
| B of A Securities | 9 | 67% | +34% |
| Credit Suisse | 8 | 88% | +30% |
Is Cardinal Health overvalued, and is it a good time to buy Cardinal Health right now? If you're wondering, here's a recap to make up your own mind: Cardinal Health's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Cardinal Health | Sector median (Health Care) |
|---|---|---|
| P/E | 33.0 | 29.4 |
| Forward P/E | 16.7 | 17.1 |
| Net margin | 1% | 12% |
π Cardinal Health is valued in line with its sector (33.0 vs 29.4).
π P/E, PEG, marginβ¦: see the glossary
π΅ Dividend : Cardinal Health pays about $2.56/share/yr β 1.08% yield. what is this?
The analyst consensus on Cardinal Health (CAH) is "Buy" (32 bullish, 0 bearish calls over 12 months). This is not advice: historically, 71% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $274 (+17% vs $235), ranging from $250 to $280 (12 analysts).
Over 1 year, 71% of analyst targets on Cardinal Health were profitable, for an average return of +28% (across 114 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $274 within 12 months, i.e. +17% vs the current price. The most bullish targets $280, the most cautious $250.
Note: analyst targets are 12-month (median $274, +17%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (71%), and the stock's past trajectory.
Its P/E is 33.0, forward P/E 16.7. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of Cardinal Health β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.